Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease

NCT05403827 is registered in ClinicalTrials.gov with Kowa Research Institute, Inc. as lead sponsor.

NCT NCT05403827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease
Lead sponsor
Kowa Research Institute, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 3, 2022
Completion date
December 5, 2023
Enrollment
644 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease